Chipscreen Biosciences Achieves FDA Approval for Groundbreaking Cancer Drug CS231295 Chipscreen Biosciences has received FDA IND approval for CS231295, a promising cancer treatment poised to advance clinical development globally.

Chipscreen Biosciences Achieves FDA Approval for Groundbreaking Cancer Drug CS231295 #China #Shenzhen #FDA_Approval #Chipscreen_Biosciences #CS231295